Abstract:Animals and animal models have been invaluable for our current understanding of human and animal biology, including physiology, pharmacology, biochemistry, and disease pathology. However, there are increasing concerns with continued use of animals in basic biomedical, pharmacological, and regulatory research to provide safety assessments for drugs and chemicals. There are concerns that animals do not provide sufficient information on toxicity and/or efficacy to protect the target population, so scientists are utilizing the principles of replacement, reduction, and refinement (the 3Rs) and increasing the development and application of new approach methods (NAMs). NAMs are any technology, methodology, approach, or assay used to understand the effects and mechanisms of drugs or chemicals, with specific focus on applying the 3Rs. Although progress has been made in several areas with NAMs, complete replacement of animal models with NAMs is not yet attainable. The road to NAMs requires additional development, increased use, and, for regulatory decision making, usually formal validation. Moreover, it is likely that replacement of animal models with NAMs will require multiple assays to ensure sufficient biologic coverage. The purpose of this manuscript is to provide a balanced view of the current state of the use of animal models and NAMs as approaches to development, safety, efficacy, and toxicity testing of drugs and chemicals. Animals do not provide all needed information nor do NAMs, but each can elucidate key pieces of the puzzle of human and animal biology and contribute to the goal of protecting human and animal health. Significance Statement Data from traditional animal studies have predominantly been used to inform human health safety and efficacy. Although it is unlikely that all animal studies will be able to be replaced, with the continued advancement in new approach methods (NAMs), it is possible that sometime in the future, NAMs will likely be an important component by which the discovery, efficacy, and toxicity testing of drugs and chemicals is conducted and regulatory decisions are made.

Food for thought - Paving the way for a UK roadmap towards optimum consumer safety: Development, Endorsement and Regulatory acceptance of New Approach Methodologies (NAMs) in Chemical Risk Assessment and Beyond

New approach methodologies in human regulatory toxicology - Not if, but how and when!

A framework for chemical safety assessment incorporating new approach methodologies within REACH

Animal-free safety assessment of chemicals: an innovation system perspective

The Road to Achieving the European Commission's Chemicals Strategy for Nanomaterial Sustainability-A PATROLS Perspective on New Approach Methodologies

Preface to the special issue of Food and Chemical Toxicology on "New approach methodologies and machine learning in food safety and chemical risk assessment: Development of reproducible, open-source, and user-friendly tools for exposure, toxicokinetic, and toxicity assessments in the 21st century"

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods

Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!

Community‐Engaged Research and the Use of Open Access ToxVal/ToxRef In Vivo Databases and New Approach Methodologies (NAM) to Address Human Health Risks From Environmental Contaminants

Consensus report on the future of animal-free systemic toxicity testing

Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience

Use of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of tobacco and other nicotine-containing products

A UK framework for the assessment and integration of different scientific evidence streams in chemical risk assessment

New approach methods to assess developmental and adult neurotoxicity for regulatory use: a PARC work package 5 project

A State-of-the-Art Review on the Alternatives to Animal Testing for the Safety Assessment of Cosmetics

Upholding the EU's Commitment to ‘Animal Testing as a Last Resort' Under REACH Requires a Paradigm Shift in How We Assess Chemical Safety to Close the Gap Between Regulatory Testing and Modern Safety Science

Utility of life stage-specific chemical risk assessments based on New Approach Methodologies (NAMs)

Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods

Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients

Next Generation Risk Assessment approaches for advanced nanomaterials: Current status and future perspectives

An industry perspective on the FDA modernization act 2.0/3.0: Potential next steps for sponsors to reduce animal use in drug development